What is it about?
To compare the bone mass density in chronic hepatitis patients before and after interferon-α treatment.
Featured Image
Why is it important?
Due to the lack of published information about the effects of IFN-α treatment on quality of life in patients with chronic HCV in Iran, it was important to study the impact of IFN-α on quality of life in patients with chronic HCV and investigate the occurrence of clinical factors associated with IFN-α therapy that induces major depression in patients.
Perspectives
Chronic hepatitis C virus infection did increase the risk of development of metabolic bone disease in this cohort. Indeed, greater reduction of bone mass density occurs in advanced liver fibrosis. The bone loss in earlier stages of chronic hepatitis C infection is likely to result from increased bone reduction rather than decreased bone formation. Overall, these observations suggest an important role for chronic hepatitis C virus infection in increased bone turnover in osteodystrophy pathogenesis
Dr Masoud Ghorbani
Pasteur Institute of Iran
Read the Original
This page is a summary of: Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha, Asian Pacific Journal of Tropical Biomedicine, February 2017, Elsevier,
DOI: 10.1016/j.apjtb.2016.11.027.
You can read the full text:
Contributors
The following have contributed to this page
